Drug Profile
Research programme: rheumatoid arthritis therapies - Provid Pharmaceuticals
Latest Information Update: 04 Apr 2008
Price :
$50
*
At a glance
- Originator Provid Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 01 Aug 2005 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)